HROW Harrow
- 10.380
- -0.260-2.44%
- 10.380
- 0.0000.00%
Harrow News
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Express News | Harrow Inc Reports 0.0% Stake in Eton Pharmaceuticals as of April 26, 2024 Vs 8.1% as of April 12, 2021 - SEC Filing
Harrow(HROW.US) 10% Shareholder Buys US$199.4K in Common Stock
$Harrow(HROW.US)$ 10% Shareholder Opaleye Management Inc. purchased 20,000 shares of common stock on Apr 25, 2024 at an average price of $9.97 for a total value of $199.4K.Source: Announcement What is
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for
Around $2M Bet On This Industrial Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Wednesday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the st
Harrow(HROW.US) 10% Shareholder Buys US$204.64K in Common Stock
$Harrow(HROW.US)$ 10% Shareholder Opaleye Management Inc. purchased 20,000 shares of common stock on Apr 23, 24, 2024 at an average price of $10.23 for a total value of $204.64K.Source: Announcement W
Over $24M Bet On RXO? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock
Harrow(HROW.US) 10% Shareholder Buys US$310.39K in Common Stock
$Harrow(HROW.US)$ 10% Shareholder Opaleye Management Inc. purchased 29,400 shares of common stock on Apr 19, 2024 at an average price of $10.5575 for a total value of $310.39K.Source: Announcement Wha
HROW, HCAT and EGRX Are Among After Hour Movers
Harrow Health Initiated at Buy by Craig-Hallum
Harrow Health Initiated at Buy by Craig-Hallum
Harrow Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/11/2024 85.9% Craig-Hallum → $24 Initiates Coverage On → Buy 03/22/2024 101.39% B. Riley Securities $30
Express News | Harrow, Inc. : Craig-Hallum Initiates Coverage With Buy Rating and Target Price $24
Analysts Offer Insights on Healthcare Companies: Lonza Group Ltd (Six Swiss: CH:LONN), Harrow Health (HROW) and Innoviva (INVA)
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
MELT-300 Pivotal Phase 3 Program Topline Readout Expected in Q4 2024 Melt Pharmaceuticals, Inc. ("Melt"), a clinical‐stage pharmaceutical company developing novel approaches for procedural sedation, today announced
Harrow(HROW.US) 10% Shareholder Buys US$641K in Common Stock
$Harrow(HROW.US)$ 10% Shareholder Opaleye Management Inc. purchased 50,000 shares of Common Stock on Mar 28, 2024 at an average price of $12.82 for a total value of $641K.Source: Announcement What is
CEO Mark Baum Acquires 9,000 Shares of Harrow Inc (HROW)
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view t
Harrow(HROW.US) Officer Buys US$104.31K in Common Stocks
$Harrow(HROW.US)$ Officer BAUM MARK L purchased 9,000 shares of Common Stocks on Mar 22, 2024 at an average price of $11.59 for a total value of $104.31K.Source: Announcement What is statement of chan
Harrow(HROW.US) 10% Shareholder Buys US$488.29K in Common Stocks
$Harrow(HROW.US)$ 10% Shareholder Opaleye Management Inc. purchased 50,600 shares of Common Stocks on Mar 20, 2024 at an average price of $9.65 for a total value of $488.29K.Source: Announcement What
Harrow Health's Growth Trajectory: A Buy Rating Amid Strong Product Performance and Strategic Market Investments
Analysis
Price Target
No Data
